Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266118 | 0.89 | HTT (0.74) | HTTTDP1ALOX15MAPTHPGD | |
| Hydrochloric Acid SCHEMBL2264414 | 0.88 | HTT (0.72) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL19930438 | 0.85 | KDM4E (0.63) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL19930469 | 0.84 | HTT (0.51) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL2266126 | 0.84 | HTT (0.76) | HTTTDP1ALOX15MAPTHPGD | |
| Trifluoroacetic Acid SCHEMBL3716290 | 0.81 | HTT (0.63) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL19930442 | 0.80 | DPP4 (0.58) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL21434305 | 0.79 | SMN1; SMN2 (0.74) | HTTTDP1ALOX15MAPTALDH1A1 | |
| SCHEMBL19930439 | 0.77 | AR (0.67) | HTTTDP1ALOX15MAPTHPGD | |
| SCHEMBL19930479 | 0.76 | HTT (0.56) | HTTTDP1ALOX15MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | HTT 3615/4885TDP1 1472/4885ALOX15 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.